Blood tests for Alzheimer’s disease

The impact of disease prevalence on test performance

Dr. DeMarco (University of British Columbia), Dr. Algeciras-Schimnich (Mayo Clinic) and Dr. Budelier (Tricore Labs) discuss often overlooked, but critically important, considerations in the implementation of blood-based biomarkers for Alzheimer's disease in the journal of Alzheimer's and Dementia.

Blood tests for Alzheimer’s disease: the impact of disease prevalence on test performance

Available online ahead of print: https://doi.org/10.1002/alz.13762